Sanofi and Merck to End Joint Vaccines Venture in Europe
- Split to be completed by end of 2016 if regulators allow
- Sanofi reviewed venture due to lack of promising pipeline
This article is for subscribers only.
Sanofi and Merck & Co. plan to end a two-decade-long joint venture to sell vaccines in Europe as revenue from the products dwindles.
The business, in which the companies each hold 50 percent, will be split and folded back into the parents’ operations, Merck and Sanofi said in a joint statement. The separation should be completed by the end of the year, if it doesn’t hit snags with regulators or local labor laws, they said.